Bendamustine and rituximab as first-line treatment for 14 indolent lymphoma patients

Chisako Iriyama

Presentation information

Poster Session

Sat. Oct, 13

Poster Session 2-16 Indolent lymphoma: Treatment

Sat. Oct 13, 2018 5:30 PM - 6:10 PM Poster2 (Osaka International Convention Center, 5F Main Foyer)

Chair: Shinya Rai (Department of Hematology and Rheumatology　Kindai University Faculty of Medicine)

[PS2-16-3] Bendamustine and rituximab as first-line treatment for 14 indolent lymphoma patients

Chisako Iriyama^1,2, Yuki Kojima¹, Katsuya Furukawa¹, Harumi Kato¹, Hirofumi Taji¹, Seiichi Kato³, Yasushi Yatabe³, Kazuhito Yamamoto¹ (1.Dep. Hematol. Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan, 2.Dep. Hematology, Fujita Health University, Toyoake, Japan, 3.Dep. Pathol. Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya Japan)

Abstract password authentication.
Password is written on a program and abstract book.